Printer Friendly

DIAGNON REPORTS SECOND QUARTER RESULTS

 ROCKVILLE, Md., Jan. 14 /PRNewswire/ -- Diagnon Corporation (OTC Bulletin Board: 3DIGN) reported results for its second quarter:
 DIAGNON CORPORATION
 Second Quarter Ended Nov. 30: 1992 1991
 Revenues $2,079,934 $2,175,822
 Income Before Income Tax $ 45,734 $ 130,316
 Net Income $ 24,434 $ 84,116
 Earnings Per Share $0.00 $0.02
 Number of Shares Outstanding 5,398,244 5,398,244
 Six Months Ended Nov. 30:
 Revenues $4,357,903 $3,973,440
 Income Before Income Tax $ 168,343 $ 180,505
 Net Income Before Cumulative
 Effect of Change in Accounting $ 106,843 $ 113,405
 Cumulative Effect of Change
 in Accounting $ 0 $1,224,000
 Net Income $ 106,843 $1,337,405
 Earnings Per Share Before
 Cumulative Effect of Change
 in Accounting $0.02 $0.02
 Cumulative Effect of Change
 in Accounting Per Share $0.00 $0.23
 Net Earnings Per Share $0.02 $0.25
 Number of Shares Outstanding 5,398,244 5,398,244
 During the fourth quarter of 1992, and effective June 1, 1991, the company adopted SFAS No. 109, "Accounting for Income Taxes." The change recognizes the value of the company's deferred tax assets.
 Diagnon's common stock is carried on the OTC Bulletin Board under the symbol 3DIGN.
 -0- 1/14/93
 /CONTACT: John C. Landon, chief executive officer, Diagnon, 301-251-2801/
 (3DIGN)


CO: Diagnon Corporation ST: Maryland IN: CPR SU: ERN

TW -- DC001 -- 4709 01/14/93 08:40 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1993
Words:236
Previous Article:GENCORP FISCAL 1992 EARNINGS
Next Article:CALTECH PROFESSOR JACQUELINE BARTON ELECTED TO DOW'S BOARD OF DIRECTORS
Topics:


Related Articles
Endocare Reports Second Quarter 1998 Financial Results Revenues Up 160% Over Second Quarter 1997
Diagnon Corporation Enters the 'Nutraceutical' Market by Launching Two New Veterinary Products, Immugam and Minigam.
Diagnon Announces Financial Results for First Quarter.
Second Patent Issued to Diagnon Corporation for Improved Laboratory Primate Environments.
Diagnon Corporation Announces Second Quarter Revenues and Sales.
Diagnon Corporation Announces Release of the Corporate Website.
Diagnon Corporation Reports Results for its Third Quarter.
Diagnon Corporation Announces Intent to Merge With Subsidiary BIOQUAL, Inc. and to Change Name to BIOQUAL, Inc.
Diagnon Presents Financial Results for Fiscal Year Ended May 31, 1999.
Diagnon Corporation Announces First Quarter Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters